Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study


Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J., Schlingemann R. O. , Axer-Siegel R., ...Daha Fazla

OPHTHALMOLOGY, cilt.118, ss.831-839, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 118 Konu: 5
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1016/j.ophtha.2010.09.004
  • Dergi Adı: OPHTHALMOLOGY
  • Sayfa Sayıları: ss.831-839

Özet

Objective: To demonstrate noninferiority of a quarterly treatment regimen to a monthly regimen of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).